• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

用于新型药物发现的PI3K检测方法的开发与应用。

Development and application of PI3K assays for novel drug discovery.

作者信息

Yanamandra Mahesh, Mitra Sayan, Giri Archana

机构信息

Scientist, GVK Biosciences Private Ltd, Biology , Campus MLR 1, Survey Nos. 125 (part) and 126, IDA Mallapur, Hyderabad, Telangana, 500076 , India +91 9989086492 ;

出版信息

Expert Opin Drug Discov. 2015 Feb;10(2):171-86. doi: 10.1517/17460441.2015.997205. Epub 2014 Dec 30.

DOI:10.1517/17460441.2015.997205
PMID:25547459
Abstract

INTRODUCTION

Phosphoinositide 3-kinases (PI3Ks) constitute one of the most important signaling pathways, playing a vital role in cellular differentiation and proliferation with a key function in cellular receptor triggered signal transduction downstream of tyrosine kinase receptors and/or G-protein coupled receptors. PI3K promotes cell survival proliferation, protein synthesis and glucose metabolism by generating secondary messengers phospholipid phosphatidyl 3,4,5-triphosphate and signaling via AKT/mTOR regulation. Deregulation of PI3K pathways have been observed in cancer, diabetes, neurological and inflammatory diseases and is an attractive target for pharmaceutical industries.

AREAS COVERED

In this review, the authors explain different PI3K assay methodologies. Furthermore, the authors summarize the techno-scientific principles and their utility in profiling novel chemical entities against PI3Ks. Specifically, the authors compare different PI3K assay formats explaining their mode of detection as well as their advantages and limitations for drug discovery efforts.

EXPERT OPINION

Developing lipid (PI3K) kinase assays involves significant effort and a rational understanding is needed due to the intrinsic lipidic nature of phospholipid phosphatidyl 4,5-biphosphate, which is used as an in vitro substrate for assays with PI3K isoforms. The assay of choice should be versatile, homogenous and definitely adaptable for high-throughput screening campaigns. Additionally, these assays are expected to dissect the mechanism of action of novel compounds (inhibitor characterization) against PI3K. Existing methods provide the versatility to medicinal chemists such that they can choose one or more assay platform to progress their compounds while profiling and/or inhibitor characterization.

摘要

引言

磷酸肌醇3激酶(PI3Ks)构成了最重要的信号通路之一,在细胞分化和增殖中发挥着至关重要的作用,在酪氨酸激酶受体和/或G蛋白偶联受体下游的细胞受体触发信号转导中起关键作用。PI3K通过生成二级信使磷脂酰3,4,5-三磷酸并经由AKT/mTOR调节发出信号,从而促进细胞存活、增殖、蛋白质合成和葡萄糖代谢。在癌症、糖尿病、神经和炎症性疾病中已观察到PI3K通路失调,它是制药行业有吸引力的靶点。

涵盖领域

在本综述中,作者解释了不同的PI3K检测方法。此外,作者总结了技术科学原理及其在分析针对PI3Ks的新型化学实体方面的用途。具体而言,作者比较了不同的PI3K检测形式,解释了它们的检测模式以及在药物发现工作中的优缺点。

专家观点

开发脂质(PI3K)激酶检测方法需要付出巨大努力,由于用作PI3K亚型检测体外底物的磷脂酰4,5-二磷酸具有内在的脂质性质,因此需要合理的理解。所选择的检测方法应具有通用性、均一性,并且肯定适用于高通量筛选活动。此外,预计这些检测方法能够剖析新型化合物(抑制剂特性)针对PI3K的作用机制。现有方法为药物化学家提供了通用性,使他们在分析和/或抑制剂特性研究时可以选择一个或多个检测平台来推进他们的化合物研究。

相似文献

1
Development and application of PI3K assays for novel drug discovery.用于新型药物发现的PI3K检测方法的开发与应用。
Expert Opin Drug Discov. 2015 Feb;10(2):171-86. doi: 10.1517/17460441.2015.997205. Epub 2014 Dec 30.
2
A versatile high-throughput screen for inhibitors of lipid kinase activity: development of an immobilized phospholipid plate assay for phosphoinositide 3-kinase gamma.一种用于脂质激酶活性抑制剂的通用高通量筛选方法:针对磷脂酰肌醇3激酶γ的固定化磷脂板检测法的开发
J Biomol Screen. 2002 Oct;7(5):441-50. doi: 10.1177/108705702237676.
3
Development of phosphocellulose paper-based screening of inhibitors of lipid kinases: case study with PI3Kβ.基于磷酸纤维素纸的脂质激酶抑制剂筛选方法的建立:以 PI3Kβ为例。
Anal Biochem. 2014 Mar 15;449:132-8. doi: 10.1016/j.ab.2013.12.029. Epub 2013 Dec 29.
4
Structure and ligand-based design of mTOR and PI3-kinase inhibitors leading to the clinical candidates VS-5584 (SB2343) and SB2602.mTOR 和 PI3-激酶抑制剂的结构和基于配体的设计导致临床候选药物 VS-5584(SB2343)和 SB2602。
J Chem Inf Model. 2014 Nov 24;54(11):3238-50. doi: 10.1021/ci500493m. Epub 2014 Oct 23.
5
Selective and potent small-molecule inhibitors of PI3Ks.PI3K的选择性强效小分子抑制剂。
Future Med Chem. 2014 May;6(7):737-56. doi: 10.4155/fmc.14.28.
6
Development of LanthaScreen cellular assays for key components within the PI3K/AKT/mTOR pathway.用于PI3K/AKT/mTOR信号通路关键组分的LanthaScreen细胞分析方法的开发。
J Biomol Screen. 2009 Feb;14(2):121-32. doi: 10.1177/1087057108328132. Epub 2009 Feb 4.
7
A robust screen for inhibitors and enhancers of phosphoinositide-3 kinase (PI3K) activities by ratiometric fluorescence superquenching.
J Biomol Screen. 2006 Jun;11(4):413-22. doi: 10.1177/1087057106286402. Epub 2006 Feb 20.
8
Methods to measure the enzymatic activity of PI3Ks.测量PI3Ks酶活性的方法。
Methods Enzymol. 2014;543:115-40. doi: 10.1016/B978-0-12-801329-8.00006-4.
9
Inhibition of PI3K signaling spurs new therapeutic opportunities in inflammatory/autoimmune diseases and hematological malignancies.PI3K 信号抑制为炎症/自身免疫性疾病和血液系统恶性肿瘤带来新的治疗机会。
Pharmacol Rev. 2012 Oct;64(4):1027-54. doi: 10.1124/pr.110.004051.
10
Protein-protein interaction modulator drug discovery: past efforts and future opportunities using a rich source of low- and high-throughput screening assays.蛋白质-蛋白质相互作用调节剂药物发现:利用丰富的低通量和高通量筛选试验的过往努力与未来机遇
Expert Opin Drug Discov. 2014 Dec;9(12):1393-404. doi: 10.1517/17460441.2014.954544. Epub 2014 Nov 6.

引用本文的文献

1
miR-1908 Dysregulation in Human Cancers.人类癌症中miR-1908的失调
Front Oncol. 2022 Apr 7;12:857743. doi: 10.3389/fonc.2022.857743. eCollection 2022.
2
Microglia Mediated Neuroinflammation: Focus on PI3K Modulation.小胶质细胞介导的神经炎症:聚焦于PI3K调节
Biomolecules. 2020 Jan 14;10(1):137. doi: 10.3390/biom10010137.
3
Novel Isoquinolinamine and Isoindoloquinazolinone Compounds Exhibit Antiproliferative Activity in Acute Lymphoblastic Leukemia Cells.新型异喹啉胺和异吲哚并喹唑啉酮化合物在急性淋巴细胞白血病细胞中表现出抗增殖活性。
Biomol Ther (Seoul). 2019 Sep 1;27(5):492-501. doi: 10.4062/biomolther.2018.199.
4
Telmisartan Protects a Microglia Cell Line from LPS Injury Beyond AT1 Receptor Blockade or PPARγ Activation.替米沙坦通过阻断 AT1 受体或激活 PPARγ以外的机制来保护小胶质细胞系免受 LPS 损伤。
Mol Neurobiol. 2019 May;56(5):3193-3210. doi: 10.1007/s12035-018-1300-9. Epub 2018 Aug 13.